author-photo

Luca Frison

University of Padua

19

Papers

98

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

2017 Blood
Show All
- Source
- Cite
- Save
Citations (50)
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure

2016
Show All
- Source
- Cite
- Save
Citations (0)
Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients.

2015 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC

2015 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors

2014 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The “Gruppo Triveneto LMC”

2013 Blood
Show All
- Source
- Cite
- Save
Citations (0)